Q-omics provides the consensus-scored MIR591 profile across patient tissues and cancer cell-line models. MIR591 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, MIR591 is differentially expressed in 2, with the highest sampling consensus in STAD. Additionally, MIR591 RNA expression shows 8,745 significant gene co-expression associations, with the highest sampling consensus in BRCA. Together, these results highlight STAD, and BRCA as cancer lineages where MIR591 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR591 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR591 survival associations across molecular data types. MIR591 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR591 RNA expression–survival associations across cancer types. High MIR591 expression shows unfavorable associations in STAD, BLCA, LIHC, UVM, ESCA and THYM. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify STAD as the clearest survival context for MIR591 RNA expression.
This table summarizes MIR591 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR591. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR591 shows lower tumor expression in STAD and higher tumor expression in LUAD. The STAD box plot shows higher MIR591 RNA expression in normal versus tumor tissue (log2 FC = −0.980, t-test p = .003).
This table shows molecular features associated with MIR591 in patient tissues and cancer cell lines. In patient samples, MIR591 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
